natgillin/translations-raw huggingface dataset:
The other two active substances, abacavir and lamivudine, are nucleoside reverse- transcriptase inhibitors (NRTIs).
Druge dvije djelatne tvari, abakavir i lamivudin inhibitori su enzima reverzne transkriptaze nukleozida (NRTI-ovi).
The other two studies (516 patients) examined the effects of Xyrem on excessive daytime sleepiness and other symptoms of narcolepsy, either taken alone or as an add-on to the patient’s existing dose of modafinil (a stimulant medicine used to treat narcolepsy).
Druga dva ispitivanja (516 bolesnika) proučavala su učinke lijeka Xyrem na prekomjernu dnevnu pospanost i druge simptome narkolepsije ili kad se lijek uzimao sam ili kao dodatak postojećoj bolesnikovoj dozi modafinila (stimulirajući lijek koji se koristi za liječenje narkolepsije).
The other two studies compared ritonavir-boosted Prezista with other protease inhibitors chosen on the basis of the patient’s previous treatments and predicted response, in a total of 628 patients who had taken many anti-HIV medicines in the past.
Druga dva ispitivanja uspoređivala su ritonavirom potpomognut lijek Prezista s drugim inhibitorima proteaze odabranim na temelju prethodnih bolesnikovih terapija i predviđenog odgovora kod ukupno 628 bolesnika koji su uzimali mnoge lijekove protiv HIV-a u prošlosti.
The other two studies in rheumatoid arthritis showed that Kineret was more effective than placebo when used as an add-on to methotrexate.
U druga dva ispitivanja reumatoidnog artritisa dokazano je da je lijek Kineret djelotvorniji od placeba ako se primjenjuje kao dodatak lijeku metotreksatu.
The other two studies involved a total of 1,159 patients with later stage disease, where Azilect was added to the patients’ existing treatment including levodopa.
U ostalim dvama ispitivanjima sudjelovalo je 1159 bolesnika u kasnijoj fazi bolesti, a lijek Azilect dodan je postojećoj terapiji, koja je uključivala levodopu.
The other two studies lasted longer: one compared Sycrest with olanzapine over nine weeks in patients who had come from the short-term studies; and the other was a 12-week ‘add on’ study, in which 326 patients who were already being treated with another medicine (lithium or valproic acid) were also given either Sycrest or placebo.
Druga dva ispitivanja trajala su dulje: u jednom je lijek Sycrest uspoređen s olanzapinom tijekom devet tjedana u bolesnika koji su bili prethodno uključeni u kratkotrajna ispitivanja; drugo je bilo ispitivanje lijeka kao „dodatka” tijekom 12 tjedana, u kojem je 326 bolesnika koji su već primali terapiju drugim lijekom (litijem ili valproičnom kiselinom) također primilo lijek Sycrest ili placebo.
The other two subjects used doses up to 30 IU/kg and 33 IU/kg.
Drugo dvoje ispitanika koristilo je doze do 30 IU/kg i 33 IU/kg.
The otheringredients are lactose monohydrate, low-substituted hydroxypropyl cellulose, tartaric acid, sodium laurylsulfate and magnesium stearate in the tablet core as well as lecithin (soybeans), poly(vinyl alcohol), talc, titanium dioxide (E 171) and xanthan gum in the film-coating.
Ostali sastojci su laktoza hidrat, niskosupstituirana hidroksipropilceluloza, tartarna kiselina, natrijev laurilsulfat i magnezijev stearat u jezgri tablete kao i lecitin (sojin), poli(vinilni alkohol), talk, titanijev dioksid (E 171) i ksantanska guma u film ovojnici.
The outcome was reported as recovered in eight cases, improved in two cases, unchanged at time of reporting in five and unknown in 10 cases.
Prijavljeni ishod bio je oporavak u 8 slučajeva, poboljšanje u 2 slučaja, nepromijenjeno stanje u trenutku izvještavanja u 5 slučajeva i nepoznat ishod u 10 slučajeva.
The outer and intermediate package should be checked to verify the product and patient-specific- label located on the top of the box and on the intermediate bag.
Vanjsko i intermedijarno pakiranje potrebno je provjeriti kako bi se potvrdilo da se radi o odgovarajućem lijeku i da naljepnica koja se nalazi na gornjoj strani kutije te na intermedijarnoj vrećici odgovara određenom bolesniku.
The outer cap should be kept to remove the used needle.
Vanjski zatvarač treba sačuvati radi uklanjanja upotrijebljene igle.
The outer layer is beige and labelled with the following:
Vanjski je sloj bež boje i označen sljedećim oznakama:
The outer shipping box should be opened to verify the product and patient-specific labels located on the top of the insulated container.
Vanjsku transportnu kutiju potrebno je otvoriti kako bi se provjerilo lijek i naljepnice s podacima o bolesniku koje se nalaze na vrhu izoliranog spremnika.
The outer surface of the backing layer is imprinted with ‘capsaicin 8%’.
Na vanjskoj površini potpornog sloja otisnuto je ‘capsaicin 8%’.
The outer surface of the backing layer is imprinted with ‘capsaicin 8%’.
Na vanjskoj strani potpornog sloja otisnuto je ‘capsaicin 8%’.
The outside is tan-coloured and is imprinted with Leganto 1 mg/24 h.
Vanjska strana je boje kože s otisnutim natpisom Leganto 1 mg/24 h.
The outside is tan-coloured and is imprinted with Leganto 3 mg/24 h.
Vanjska strana je boje kože s otisnutim natpisom Leganto 3 mg/24 h.
The outside is tan-coloured and is imprinted with Leganto 4 mg/24 h.
Vanjska strana je boje kože s otisnutim natpisom Leganto 4 mg/24 h.
The outside is tan-coloured and is imprinted with Leganto 6 mg/24 h.
Vanjska strana je boje kože s otisnutim natpisom Leganto 6 mg/24 h.
The outside is tan-coloured and is imprinted with Leganto 8 mg/24 h.
Vanjska strana je boje kože s otisnutim natpisom Leganto 8 mg/24 h.
The outside is tan-coloured and is imprinted with Neupro 1 mg/24 h.
Vanjska strana je boje kože s otisnutim natpisom Neupro 1 mg/24 h.
The outside is tan-coloured and is imprinted with Neupro 3 mg/24 h.
Vanjska strana je boje kože s otisnutim natpisom Neupro 3 mg/24 h.
The outside is tan-coloured and is imprinted with Neupro 4 mg/24 h.
Vanjska strana je boje kože s otisnutim natpisom Neupro 4 mg/24 h.
The outside is tan-coloured and is imprinted with Neupro 6 mg/24 h.
Vanjska strana je boje kože s otisnutim natpisom Neupro 6 mg/24 h.
The outside is tan-coloured and is imprinted with Neupro 8 mg/24 h.
Vanjska strana je boje kože s otisnutim natpisom Neupro 8 mg/24 h.
The outside of the backing layer is beige and labelled with “Exelon”,
Vanjski dio potpornog sloja je bež boje s oznakama „Exelon“,
The outside of the backing layer is beige and labelled with “Prometax”,
Vanjski dio potpornog sloja je bež boje s oznakama „Prometax“,
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 1 mg/24 h’.
Vanjski potporni sloj jest boje kože s otisnutim „Leganto 1 mg/24 h“.
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 2 mg/24 h’.
Vanjski potporni sloj jest boje kože s otisnutim „Leganto 2 mg/24 h“.
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 3 mg/24 h’.
Vanjski potporni sloj jest boje kože s otisnutim „Leganto 3 mg/24 h“.
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 4 mg/24 h’.
Vanjski potporni sloj jest boje kože s otisnutim „Leganto 4 mg/24 h“.
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 6 mg/24 h’.
Vanjski potporni sloj jest boje kože s otisnutim „Leganto 6 mg/24 h“.
The outside of the backing layer is tan-coloured and imprinted with ‘Leganto 8 mg/24 h’.
Vanjski potporni sloj jest boje kože s otisnutim „Leganto 8 mg/24 h“.
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 1 mg/24 h’.
Vanjski potporni sloj jest boje kože s otisnutim „Neupro 1 mg/24 h“.
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 2 mg/24 h’.
Vanjski potporni sloj jest boje kože s otisnutim „Neupro 2 mg/24 h“.
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 3 mg/24 h’.
Vanjski potporni sloj jest boje kože s otisnutim „Neupro 3mg/24 h“.
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 4 mg/24 h’.
Vanjski potporni sloj jest boje kože s otisnutim „Neupro 4 mg/24 h“.
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 6 mg/24 h’.
Vanjski potporni sloj jest boje kože s otisnutim „Neupro 6 mg/24 h“.
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 8 mg/24 h’.
Vanjski potporni sloj jest boje kože s otisnutim „Neupro 8 mg/24 h“.
The outside of the OptiSet can be cleaned by wiping it with a damp cloth.
Vanjski dio OptiSet brizgalice može se prebrisati vlažnom krpom.
The overall accuracy of technetium Tc 99m tilmanocept for identification of true positive and true negative patients relative to pathology in the localised lymph nodes was 98.80%.
Cjelokupna točnost tilmanocepta obilježenog radioaktivnim tehnecijem Tc 99m u identifikaciji stvarno pozitivnih i stvarno negativnih bolesnika u odnosu na patološki nalaz u lokaliziranim limfnim čvorovima iznosila je 98,80%.
The overall change in WHO functional class during both studies was significantly better among bosentan-treated patients as compared with placebo-treated patients.
Ukupna promjena WHO funkcijskog stanja tijekom obje studije bila je znatno bolja među bolesnicima koji su dobivali bosentan u odnosu na one koji su dobivali placebo.
The overall clearance of amifampridine is predominantly due to metabolism by N-acetylation and acetylator phenotype has a greater effect on an individual’s metabolism and elimination of amifampridine than does elimination by renal function (See Table 4).
Ukupan klirens amifampridina najvećim dijelom ovisi o metabolizmu putem N-acetilacije te fenotip acetilatora ima veći utjecaj na metabolizam i eliminaciju amifampridina u pojedinca nego što ima eliminacija putem bubrežne funkcije (vidjeti tablicu 4).
The overall decision of the visual PET scan assessment is subject-based and based on a binary outcome as ‘positive’ or ‘negative‘.
Krajnja odluka o vizualnoj procjeni slike dobivene PET-om ovisi o ispitaniku, a temelji se na binarnom ishodu kao 'pozitivno' ili 'negativno'.
The overall duration of treatment is at the specialist physician’s discretion (see section 4.4).
Cjelokupno trajanje liječenja ovisi o procjeni liječnika specijaliste (vidjeti dio 4.4.).
The overall duration of treatment with i.v. lacosamide is at the physician’s discretion; there is experience from clinical trials with twice daily infusions of lacosamide for up to 5 days
Ukupno trajanje liječenja i.v. lakozamidom ocjenjuje liječnik: postoji iskustvo iz kliničkih istraživanja s infuzijama lakozamida dvaput dnevno do 5 dana.
The overall evidence suggests a possible increased risk of breast cancer in women taking oestrogen- only therapy that is dependent on the duration of therapy.
Cjelokupni dokazi ukazuju na mogući povećani rizik od karcinoma dojke u žena koje uzimaju terapiju samim estrogenom, ovisno o trajanju terapije.
The overall exposure and Cmax of parathyroid hormone were slightly increased (22% and 56%, respectively) in a group of 8 male and 8 female subjects with mild-to-moderate renal impairment (creatinine clearances of 30 to 80 mlmin) compared with a matched group of 16 subjects with normal renal function.
Ukupna izloženost i Cmax paratireoidnog hormona bila je blago povećana (22%, odnosno 56%) u grupi od 8 žena i 8 muškaraca sa blagim do umjerenim oštećenjem bubrega (klirens kreatinina od 30-80 ml/min) u odnosu na odgovarajuću grupu od 16 osoba sa normalnom bubrežnom funkcijom.
The overall exposure of liraglutide was equivalent following administration of Xultophy versus liraglutide alone while Cmax was lower by 23%.
Ukupna izloženost liraglutidu nakon primjene lijeka Xultophy bila je ekvivalentna onoj nakon primjene samog liraglutida, dok je Cmax bio 23% niži.
The overall frequency of volume depletion (including the predefined terms blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolaemia, orthostatic hypotension, and syncope) was similar in patients treated with empagliflozin (empagliflozin 10 mg: 0.5%, empagliflozin 25 mg: 0.3%) and placebo (0.3%).
Sveukupna učestalost deplecije volumena (uključujući prethodno definirane pojmove sniženi krvni tlak (izmjeren ambulantno ), sniženi sistolički krvni tlak, dehidraciju, hipotenziju, hipovolemiju, ortostatsku hipotenziju i sinkopu) bila je slična u bolesnika liječenih empagliflozinom (empagliflozin 10 mg: 0,5%, empagliflozin 25 mg: 0,3%) i placebom (0,3%).
The overall incidence and pattern of adverse reactions reported with Kinzalkomb 80 mg/25 mg was comparable with Kinzalkomb 80 mg/12.5 mg.
Ukupna incidencija i obrazac nuspojava prijavljenih uz Kinzalkomb 80 mg/25 mg usporedivi su s Kinzalkomb 80 mg/12,5 mg.
The overall incidence and pattern of adverse reactions reported with MicardisPlus 80 mg/25 mg was comparable with MicardisPlus 80 mg/12.5 mg.
Ukupna incidencija i obrazac nuspojava prijavljenih uz MicardisPlus 80 mg/25 mg usporedivi su s MicardisPlus 80 mg/12,5 mg.
The overall incidence and pattern of adverse reactions reported with PritorPlus 80 mg/25 mg was comparable with PritorPlus 80 mg/12.5 mg.
Ukupna incidencija i obrazac nuspojava prijavljenih uz PritorPlus 80 mg/25 mg usporedivi su s PritorPlus 80mg/12,5mg.
The overall incidence and pattern of adverse reactions reported with telmisartan/hydrochlorothiazide 80 mg/25 mg was comparable with telmisartan/hydrochlorothiazide 80 mg/12.5 mg.
Ukupna incidencija i obrazac nuspojava prijavljenih uz telmisartan/hidroklportiazid 80 mg/25 mg usporedivi su s onima telmisartana/hidroklorotiazida 80 mg/12,5 mg.
The overall incidence in Tarceva-treated patients from all studies (including uncontrolled studies and studies with concurrent chemotherapy) is approximately 0.6% compared to 0.2% in patients on placebo.
Ukupna incidencija IBP u bolesnika liječenih lijekom Tarceva temeljem svih ispitivanja (uključujući ispitivanja bez kontrolne skupine te ispitivanja primjene lijeka Tarceva u kombinaciji s kemoterapijom) iznosi oko 0,6%, u usporedbi s 0,2% u bolesnika koji su primali placebo.
The overall incidence of adverse events in patients treated with Onglyza in this trial was similar to placebo (72.5% versus 72.2%, respectively ).
Ukupna incidencija nuspojava u bolesnika liječenih lijekom Onglyza u tom ispitivanju bila je slična onoj primijećenoj u bolesnika koji su primali placebo (72,5% naspram 72,2%).
The overall incidence of adverse events related to depression and suicidal ideation was 8% for both Plegridy 125 micrograms every 2 weeks and placebo groups.
Ukupna incidencija štetnih događaja vezanih uz depresiju i suicidalne ideacije bila je 8% za obje skupine, skupinu koja je dobivala 125 mikrograma Plegridyja svaka 2 tjedna i placebo skupinu.
The overall incidence of adverse reactions reported with PritorPlus was comparable to those reported with telmisartan alone in randomised controlled trials involving 1471 patients randomised to receive telmisartan plus hydrochlorothiazide (835) or telmisartan alone (636).
Ukupna incidencija nuspojava prijavljenih uz PritorPlus usporediva je s onima prijavljenima uz sami telmisartan u randomiziranim kontroliranim ispitivanjima koja uključuju 1471 bolesnika randomiziranih za dobivanje telmisartana plus hidroklorotiazid (835) ili samog telmisartana (636).
The overall incidence of adverse reactions reported with telmisartan was usually comparable to placebo (41.4% vs 43.9 %) in controlled trials in patients treated for hypertension.
Ukupna incidencija nuspojava zabilježenih s telmisartanom bila je uobičajeno usporediva s placebom (41,4 % u odnosu na 43,9 %), u kontroliranim ispitivanjima u bolesnika liječenih zbog hipertenzije.
The overall incidence of any factor VIII inhibitor development (low or high) was 0.4% (1 of 233).
Ukupna incidencija svih razvoja inhibitora faktora VIII (nizak ili visok) bila je 0,4% (1 od 233).
The overall incidence of diarrhoea, gastrointestinal and abdominal pain, asthenic conditions, upper respiratory tract infections and peripheral neuropathies were 12%-15% lower in the subcutaneous group than in the intravenous group.
Ukupna incidencija proljeva, gastrointestinalne i abdominalne boli, astenijskih stanja, infekcija gornjih dišnih putova i perifernih neuropatija, bila je 12 % – 15 % niža u skupini supkutane primjene nego u intravenskoj skupini.
The overall incidence of drug-related diarrhoea was 22 %, including 4 % with Grade 3 and 0.4 % with Grade 4.
Ukupna incidencija proljeva povezanog s uzimanjem lijeka bila je 22%, uključujući 4% sa stupnjem 3, i 0,4% sa stupnjem 4.
The overall incidence of elevated serum potassium was higher in patients with moderate renal impairment with incidences of 7.5%, 12.3%, and 8.1% on canagliflozin 100 mg, canagliflozin 300 mg, and placebo, respectively.
Ukupna incidencija povišenog kalija u serumu bila je viša u bolesnika s umjerenim oštećenjem bubrega uz kanagliflozin od 100 mg, kanagliflozin od 300 mg, odnosno placebo s incidencijama od 7,5%; 12,3% i 8,1%.
The overall incidence of hepatitis B infections was similar in patients treated with BzmbR-CAP or with R-CHOP (0.8% vs 1.2% respectively).
Ukupna incidencija infekcija hepatitisom B bila je slična u bolesnika liječenih s BzmbR-CAP i liječnih s R-CHOP (0,8 % odnosno 1,2 %).
The overall incidence of hepatitis B infections was similar in patients treated with BzR-CAP or with R-CHOP (0.8% vs 1.2% respectively).
Ukupna incidencija infekcija hepatitisom B bila je slična u bolesnika liječenih s BzR-CAP i liječnih s R-CHOP (0,8% odnosno 12%).
The overall incidence of hepatitis B infections was similar in patients treated with VcR-CAP or with R-CHOP (0.8% vs 1.2% respectively).
Ukupna incidencija infekcija hepatitisom B bila je slična u bolesnika liječenih s VcR-CAP i liječnih s R-CHOP (0,8% odnosno 12%).
The overall incidence of IRRs in clinical trials was 23% with the first infusion and decreased with subsequent infusions.
Ukupna incidencija reakcija povezanih s infuzijom u kliničkim ispitivanjima bila je 23% nakon prve infuzije te se smanjivala s narednim infuzijama.
The overall incidence of NCI-CTC Grade 3 and 4 hypertension in patients receiving Avastin ranged from 0.4% to 17.9%.
Ukupna incidencija hipertenzije stupnja 3 i 4 prema NCI-CTC kriterijima u bolesnika koji su primali Avastin kretala se od 0,4% do 17,9%.
The overall incidence of renal and urinary adverse events was similar for Tecfidera and placebo-treated patients.
Ukupna incidencija bubrežnih i urinarnih štetnih događaja bila je slična u bolesnika koji su liječeni Tecfiderom i koji su dobivali placebo.
The overall incidence of serious adverse reactions was low and did not indicate any specific system organ involvement.
Sveukupna incidencija ozbiljnih nuspojava bila je niska i nije ukazivala na zahvaćenost nijednog određenog organskog sustava.
The overall incidence of these is slightly higher with Rebif 44 than Rebif 22 micrograms.
Ukupna incidencija ove pojave je nešto viša kod lijeka Rebif 44 mikrograma nego kod Rebif 22 mikrograma.
The overall incidence of these is slightly higher with Rebif 44 than Rebif 22 micrograms.
Ukupna incidencija ove pojave je nešto viša kod lijeka Rebif od 44 mikrograma negó kod Rebif 22 mikrograma.
The overall incidence of transaminase increases >3 xULN (not necessarily comprising an adverse event) in the voriconazole clinical programme was 18.0% (319/1768) in adults and 25.8% (73/283) in paediatric subjects who received voriconazole for pooled therapeutic and prophylaxis use.
Ukupna incidencija povećanja vrijednosti transaminaza >3 x ULN (ne nužno uključujući i nuspojavu) u ispitanika koji su u kliničkim ispitivanjima primali vorikonazol iznosila je 18,0 % (319/1768) ) u odraslih i 25,8% (73/283) kod pedijatrijskih ispitanika koji su primili vorikonazol u kombiniranu terapeutsko- profilaktičku svrhu.
The overall mean age was 59.4 years; 56.6% of patients had an ECOG performance status of 0, 43% had a value of 1 and 0.4% had a value of 2.
Prosječna ukupna dob iznosila je 59,4 godine; 56,6% bolesnika imalo je ECOG status 0, njih 43% status 1, a 0,4% status 2.
The overall median double-blind treatment duration was 115 weeks (up to a maximum of 188 weeks on macitentan).
Ukupni medijan trajanja dvostruko slijepog liječenja iznosio je 115 tjedana (do maksimalno 188 tjedana na macitentanu).
The overall median time since most recent progression or relapse to randomization was 6 weeks.
Ukupni medijan vremena od zadnje progresije ili relapsa bolesti do randomizacije iznosio je 6 tjedana.
The overall objective response rates in the all-randomised population (investigator assessment) were 25.7% (capecitabine) vs.
Ukupni terapijski odgovor u cijeloj randomiziranoj populaciji (prema prosudbi istraživača) bio je 25,7% (kapecitabin) nasuprot 16,7% (Mayo protokol), p < 0,0002.
The overall objective response rates in the all-randomised population (investigator assessment) were 41.6% (capecitabine + docetaxel) vs.
Ukupni terapijski odgovor u cijeloj randomiziranoj populaciji (procjena istraživača) iznosio je 41,6% (kombinacija kapecitabina i docetaksela), odnosno 29,7% (samo docetaksel), p=0,0058.
The overall objective response rates in the all-randomised population (investigator assessment) were 41.6% (docetaxel + capecitabine) vs.
Ukupna objektivna stopa terapijskog odgovora u svih randomiziranih bolesnika (prema procjeni ispitivača) bila je 41,6% (docetaksel + kapecitabin) u odnosu na 29,7% (samo docetaksel); p=0,0058.
The overall occurrence of tuberculosis infections and non-serious herpes infections were higher for belatacept regimens than for the ciclosporin regimen.
Ukupna učestalost tuberkulozne infekcije i herpetične infekcije koja nije bila ozbiljna bila je viša uz primjenu režima belatacepta nego uz primjenu ciklosporina.
The overall percentage of patients with antibodies to Cimzia detectable on at least one occasion up to Week 24 was 11.7% in the Phase III placebo-controlled trial in patients with psoriatic arthritis.
Ukupni postotak bolesnika s antitijelima na Cimziju koja su otkrivena barem u jednoj prilici do 24. tjedna bio je 11,7% u fazi III placebom kontroliranog istraživanja u bolesnika s psorijatičnim artritisom.
The overall percentage of patients with antibodies to Cimzia detectable on at least one occasion up to Week 24 was 4.4% in the phase III placebo controlled trial in patients with axial spondyloarthritis.
Ukupni postotak bolesnika s antitijelima na Cimziju koja su otkrivena u barem jednoj prilici do 24. tjedna bio je 4,4% u fazi III placebom kontroliranog istraživanja u bolesnika s aksijalnim spondiloartritisom.
The overall percentage of treatment responders observed in study 1100.1486 (including lead-in phase), regardless of the formulation is 793/1,068 = 74.3 %.
Ukupni postotak osoba koje su odgovorile na liječenje opažen u ispitivanju 1100.1486 (uključujući uvodno razdoblje), bez obzira na formulaciju, je 793/1 068 = 74,3 %.
The overall percentage of treatment responders observed in study 1100.1486 (including lead-in phase), regardless of the formulation is 793/1,068 = 74.3 %.
Ukupni postotak osoba koje su odgovorile na liječenje opažen u ispitivanju 1100.1486 (uključujući uvodno razdoblje), bez obzira na formulaciju, je 793/1068 = 74,3 %.
The overall PFS and OS, observed in the ITT population, as determined by the core radiology laboratory assessment, are summarized in the table below:
Ukupni PFS i OS zabilježeni u populaciji svih uključenih bolesnika (ITT populacija) te utvrđeni središnjom procjenom ključnih radioloških nalaza sažeti su u sljedećoj tablici:
The overall proportion of patients who experienced an adverse reaction was 26.0 % and 28.6 % for ibandronic acid 3 mg injection every 3 months after one year and two years, respectively.
Ukupan udio bolesnika koji su imali nuspojave iznosio je 26,0% i 28,6% za injekciju ibandronatne kiseline od 3mg primijenjenu svaka tri mjeseca nakon jedne, odnosno dvije godine.
The overall proportion of patients who experienced an adverse reaction, was 22.7 % and 25.0 % for ibandronic acid 150 mg once monthly after one and two years, respectively.
Sveukupni udio bolesnika koji su imali nuspojave, iznosio je 22,7% odnosno 25% za ibandronatu kiselinu 150 mg jedanput mjesečno nakon jedne odnosno dvije godine.